Traditional drug discovery and development processes are time-consuming and expensive, often involving extensive trial-and-error experimentation to identify promising drug candidates and predict their properties. This can lead to delays in bringing effective therapeutics to market and increased costs for pharmaceutical companies.

XtalPi offers an AI-powered drug discovery platform that integrates computational modeling, machine learning, and automation to accelerate the identification and development of novel therapeutics. The platform leverages AI, quantum mechanics, and robotics to predict drug interactions, optimize lead compounds, and streamline R&D processes. By combining computational predictions with experimental validation, XtalPi reduces the time and cost associated with traditional drug discovery, enabling faster development of effective treatments. The platform offers solutions spanning digital chemistry, drug discovery, and solid-state research.

XInsight: Patent extraction tool for identifying relevant prior art and competitive landscape.

XFEP: High-accuracy free energy calculation tool for predicting binding affinities and optimizing drug candidates.

XMolGen: Generative chemistry tool for exploring novel chemical space and designing new molecules.

Automation-aided chemical synthesis for rapid and efficient production of drug candidates.

XtalGazer: Software for solid-state research and crystal structure prediction.

Hit discovery and lead optimization services leveraging AI and automation.

Biology capabilities for target validation and mechanism-of-action studies.

XtalPi's primary customers are pharmaceutical companies and research institutions seeking to accelerate their drug discovery and development efforts, reduce costs, and improve the efficiency of their R&D processes.